{"id":11129,"date":"2013-07-19T00:00:00","date_gmt":"2013-07-18T22:00:00","guid":{"rendered":"https:\/\/idibell.cat\/es\/blog\/2013\/07\/19\/descubren-una-futura-diana-terapeutica-para-el-tratamiento-del-cancer-de-pulmon\/"},"modified":"2021-11-18T12:21:19","modified_gmt":"2021-11-18T11:21:19","slug":"descubren-una-futura-diana-terapeutica-para-el-tratamiento-del-cancer-de-pulmon","status":"publish","type":"post","link":"https:\/\/idibell.cat\/es\/2013\/07\/descubren-una-futura-diana-terapeutica-para-el-tratamiento-del-cancer-de-pulmon\/","title":{"rendered":"Descubren una futura diana terap\u00e9utica para el tratamiento del c\u00e1ncer de pulm\u00f3n"},"content":{"rendered":"

Uno de los objetivos de las investigaciones en gen\u00e9tica y biolog\u00eda molecular del c\u00e1ncer es conseguir un tratamiento \u201ca la carta\u201d, es decir, que estudiando las alteraciones presentes en un tumor se pueda decidir cu\u00e1l es el f\u00e1rmaco que tendr\u00e1 un m\u00e1ximo efecto con una m\u00ednima toxicidad.<\/p>\n

Dos ejemplos recientes en este campo son los hallazgos de que pacientes con c\u00e1ncer de pulm\u00f3n portadores de mutaciones en los genes EGFR y ALK son m\u00e1s sensibles a ciertos f\u00e1rmacos con actividad inhibidora tirosin-quinasa. El problema es que todav\u00eda pocos pacientes con c\u00e1ncer muestran los mencionados defectos gen\u00e9ticos susceptibles a ser tratados con los nuevos f\u00e1rmacos.<\/p>\n

La revista Oncogene ha publicado un art\u00edculo dirigido por Manel Esteller, Director del Programa de Epigen\u00e9tica y Biolog\u00eda del C\u00e1ncer del Instituto de Investigaci\u00f3n Biom\u00e9dica de Bellvitge (IDIBELL), Investigador ICREA y Profesor de Gen\u00e9tica de la Universidad de Barcelona, que describe una nueva alteraci\u00f3n gen\u00e9tica en un oncog\u00e9n en c\u00e1ncer de pulm\u00f3n que podr\u00eda ser una buena candidata para el desarrollo de f\u00e1rmacos espec\u00edficos. \u00abHemos encontrado que entre un 5-10% de los tumores de pulm\u00f3n, en vez de tener la dosis normal del oncog\u00e9n (dos copias, una en el cromosoma materno y otra en el paterno) poseen una sobredosis del mismo, alrededor de 10 copias extras del gen\u201d ha explicado Manel Esteller, director del estudio. El oncog\u00e9n identificado origina la prote\u00edna SETDB1, una histona metiltransferasa. Se trata de una enzima que se puede inhibir con compuestos en los que la industria farmacol\u00f3gica tiene experiencia.<\/p>\n

\u201cNuestro estudio\u201d ha explicado Esteller \u201cse\u00f1ala un punto d\u00e9bil de la muralla defensiva de la c\u00e9lula tumoral que ha sido posible detectar gracias al proyecto europeo CURELUNG y ahora deseamos que alguna compa\u00f1\u00eda siga esta l\u00ednea de investigaci\u00f3n para que en un futuro se disponga de un f\u00e1rmaco aplicable en los pacientes\u201d.<\/p>\n

 <\/p>\n

Referencia del art\u00edculo<\/strong>
\nRodriguez-Paredes M, Martinez de Paz A, Sim\u00f3-Riudalbas L, Sayols S, Moutinho C, Moran S, Villanueva A, V\u00e1zquez-Cedeira M, Lazo PA, Carneiro F, Moura CS, Vieira J, Teixeira MR, Esteller M. Gene Amplification of the Histone Methyltransferase SETDB1 Contributes to Human Lung Tumorigenesis. Oncogene<\/em>, doi: 10.1038\/onc.2013.239., 2013.<\/p>\n","protected":false},"excerpt":{"rendered":"

Uno de los objetivos de las investigaciones en gen\u00e9tica y biolog\u00eda molecular del c\u00e1ncer es conseguir un tratamiento \u201ca la carta\u201d, es decir, que estudiando las alteraciones presentes en un tumor se pueda decidir cu\u00e1l es el f\u00e1rmaco que tendr\u00e1 un m\u00e1ximo efecto con una m\u00ednima toxicidad. Dos ejemplos recientes en este campo son los […]<\/p>\n","protected":false},"author":6,"featured_media":19088,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"no-sidebar","site-content-layout":"page-builder","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"default","adv-header-id-meta":"","stick-header-meta":"default","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""}},"footnotes":""},"categories":[184,286,206],"tags":[],"publishpress_future_action":{"enabled":false,"date":"2024-05-12 14:14:29","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category"},"_links":{"self":[{"href":"https:\/\/idibell.cat\/es\/wp-json\/wp\/v2\/posts\/11129"}],"collection":[{"href":"https:\/\/idibell.cat\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/idibell.cat\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/idibell.cat\/es\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/idibell.cat\/es\/wp-json\/wp\/v2\/comments?post=11129"}],"version-history":[{"count":3,"href":"https:\/\/idibell.cat\/es\/wp-json\/wp\/v2\/posts\/11129\/revisions"}],"predecessor-version":[{"id":19089,"href":"https:\/\/idibell.cat\/es\/wp-json\/wp\/v2\/posts\/11129\/revisions\/19089"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/idibell.cat\/es\/wp-json\/wp\/v2\/media\/19088"}],"wp:attachment":[{"href":"https:\/\/idibell.cat\/es\/wp-json\/wp\/v2\/media?parent=11129"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/idibell.cat\/es\/wp-json\/wp\/v2\/categories?post=11129"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/idibell.cat\/es\/wp-json\/wp\/v2\/tags?post=11129"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}